Latest news
Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.stsimplywall.st · Wed, 05 Aug 2026 11:54:25 GMTVeracyte (NASDAQ:VCYT) Shows Affordable Growth Potential - ChartMillChartMill · Wed, 05 Aug 2026 11:31:32 GMTVCYT Maintained by Morgan Stanley -- Price Target Lowered to $44 - GuruFocusGuruFocus · Tue, 04 Aug 2026 16:41:15 GMTVeracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests - simplywall.stsimplywall.st · Tue, 04 Aug 2026 00:56:15 GMTIs Veracyte (VCYT) Undervalued As Raised 2026 Outlook And Q2 Earnings Lift Interest? - simplywall.stsimplywall.st · Sun, 02 Aug 2026 10:23:57 GMTVCYT Looks 19.1% Overvalued on GF Value™ as Shares Drop Amid Ins - GuruFocusGuruFocus · Fri, 31 Jul 2026 14:43:39 GMTVCYT Looks 17.7% Overvalued on GF Value™ After Sharp Stock Drop - GuruFocusGuruFocus · Fri, 31 Jul 2026 07:00:00 GMTVCYT Looks 55.5% Overvalued on GF Value™ - GuruFocusGuruFocus · Thu, 30 Jul 2026 23:25:22 GMT